CRISPR Therapeutics AG

Industry

  • Biotechnology
    • Large Molecule
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery

Other Names/Subsidiaries

  • Casebia Therapeutics
See more in Biomedtracker

Latest on CRISPR Therapeutics AG

Scrip

Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary

 
• By Joseph Haas, Vibha Ravi, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C

Pink Sheet

Gene Editing Therapy Casgevy Now Funded In 8 Countries But French Access Withdrawn

 
• By Eliza Slawther

England’s health technology assessment (HTA) agency, NICE, has formally agreed to reimburse Vertex / CRISPR Therapeutics AG ’s CRISPR/Cas9-based gene editing therapy Casgevy (exagamglogene autotemcel

Scrip

Cancer And Blood Disorder Drugs Lead EU Novel Drug Approvals In 2024

 
• By Neena Brizmohun

A total of 37 novel drugs were approved by the European Commission in 2024, a figure only marginally higher than the 36 products that were given the go-ahead in 2023. The 2024 and 2023 figures for new

In Vivo

Only Half Of 2024’s Biggest Launches Belong To Big Pharma

 
• By Andrew McConaghie and Edwin Elmhirst

A healthy total of 61 novel drugs were approved in the US in the course of 2024, but just a handful of these look certain to generate the multi-billion dollar sales that big pharma increasingly needs.